Monoclonal Antibody to CD34
Azide Free (0.1 mg)

Clone: QBEnd-10
Isotype: Mouse IgG1
Specificity: The antibody QBEnd-10 reacts with Class II epitope on CD34 (Mucosialin), a 110-115 kDa monomeric transmembrane phosphoglycoprotein expressed on hematopoietic progenitors cells and on the most pluripotential stem cells; it is gradually lost on progenitor cells. This antibody has been also used as an endothelial marker.
HLDA V.; WS Code BP BP275
HLDA V.; WS Code E E038
HLDA V.; WS Code M MA065
HLDA V.; WS Code M MR09

Regulatory Status: RUO
Immunogen: Human endothelial vesicles
Species Reactivity: Human, Non-Human Primates
Negative Species: Rat, Bovine, Sheep, Canine (Dog)
Application:
- Flow Cytometry
- Recommended dilution: 5 µg/ml
- Immunoprecipitation
- Western Blotting
- Immunohistochemistry (paraffin sections)
- Recommended dilution: 1-2 µg/ml
- Immunohistochemistry (frozen sections)
- Functional Application
- The antibody QBEnd-10 induces homotypic adhesion of leukemic cell line.

Purity: > 95% (by SDS-PAGE)
Purification: Purified by protein-A affinity chromatography
Concentration: 1 mg/ml
Storage Buffer: Azide free phosphate buffered saline (PBS), approx. pH 7.4; 0.2 µm filter sterilized.
Storage / Stability: Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Expiration: See vial label
Lot Number: See vial label

Background: CD34 is a highly glycosylated monomeric 111-115 kDa surface protein, which is present on many stem cell populations. It is a well established stem cell marker, though its expression on human hematopoietic stem cells is reversible. CD34 probably serves as a surface receptor that undergoes receptor-mediated endocytosis and regulates adhesion, differentiation and proliferation of hematopoietic stem cells and other progenitors. CD34 expression is likely to represent a specific state of hematopoietic development that may have altered adhering properties with expanding and differentiating capabilities in both in vitro and in vivo conditions.
**References:**


And many other publications.